Michael Burry Portfolio: Top 10 Stock Picks

#8 Molina Healthcare, Inc. (NYSE: MOH)

Molina Healthcare is one of Burry’s more substantial reported investments outside the technology sector. The company provides health insurance through government-sponsored programs, including Medicaid and Medicare.

In August, Burry disclosed that he had purchased additional Molina shares at approximately $198, restoring his investment to a full-sized position. He expressed confidence in the company’s long-term prospects despite challenges facing the health insurance industry.

His investment case reflects an expectation that Molina’s underlying business can recover from its difficulties and that future policy developments could improve the operating environment. However, the company remains exposed to medical cost inflation and changes in government reimbursement policies.

Healthcare is also on the radar of other well-known investors. Abbott Laboratories is one of the top 10 picks in President Trump’s latest stock portfolio, according to his disclosures. See why Abbott made the list.

#7 QXO, Inc. (NYSE: QXO)

QXO is a building-products distribution business led by Brad Jacobs, whose investment strategy centers on expanding companies through acquisitions.

Burry reportedly established a position in QXO in September and subsequently added to his investment. Financial media coverage indicated that his exposure included both common and preferred shares.

The attraction is the possibility that Jacobs can build a substantially larger distribution business by acquiring competitors and improving operations. Such a strategy could increase the company’s scale and generate long-term value, although successful acquisitions are not guaranteed.

#6 Sprouts Farmers Market, Inc. (NASDAQ: SFM)

Sprouts Farmers Market is among the consumer companies Burry has targeted following a substantial decline in its shares. The grocery retailer specializes in fresh produce, natural foods and health-oriented products.

Burry reportedly added to Sprouts in September as he searched for value outside the crowded artificial intelligence trade. However, his October 5 trading update revealed an important change in how he managed the investment.

According to media reports earlier this month, Burry replaced his ordinary Sprouts shares with long-dated call options expiring in 2028. The adjustment came as he prepared for tax-loss selling pressure on stocks that had already suffered large declines.

The options maintain exposure to a potential recovery in Sprouts shares while limiting the initial amount of capital committed. However, they introduce expiration risk, meaning Burry could lose the entire amount paid for the options if the expected recovery does not materialize in time.

Another big retailer drew attention from fund managers this year. Brown Advisory’s Large-Cap Growth Strategy named Costco a top contributor in the first quarter of 2026, citing share gains and industry-leading traffic growth. Read the full letter here.

#5 Zoetis Inc. (NYSE: ZTS)

Zoetis, a major provider of animal healthcare products, is another beaten-down company Burry has reportedly favored.

The stock drew his attention after a substantial decline, as investors reassessed the outlook for animal health products and the company’s growth prospects. Burry has described opportunities in companies that lack the excitement of artificial intelligence investments but may offer attractive valuations.

In early October, Burry reportedly changed his Zoetis position by replacing ordinary shares with call options expiring in 2029. Media reports said this was part of a broader strategy involving investments that might face additional selling pressure during the fourth-quarter tax-loss-harvesting season.

Zoetis is down about 44% over the past year because its pet medicine sales are falling. Pet owners are visiting veterinary clinics less often and watching prices more closely, and rivals are selling cheaper skin and parasite medicines. U.S. pet sales fell 11% in the first quarter, and the stock dropped 21% in one day in May when the company missed estimates and cut its 2026 forecast. In August, it cut the forecast again, and it now expects organic revenue to fall 1% to 3% this year.

Bulls say Zoetis stock has fallen too far. It trades at about 12.6 times forward earnings, less than half its five-year average of about 27. Pet ownership and spending on animal health have grown for years, and livestock sales rose 11% in the second quarter. Zoetis is also launching new treatments, including arthritis drugs and a longer-lasting version of its skin treatment Cytopoint, which bulls expect to bring growth back to pet medicine. Its gross margin is still about 73%, so each new sale adds a lot of profit.

Other investors are also looking at healthcare to diversify away from AI stocks. Jim Cramer and billionaire Ken Fisher both like AbbVie. Read the full analysis here.